CN103211828B - Rhizoma Panacis Japonici saponin IV is preparing the application in blood lipid-lowering medicine - Google Patents
Rhizoma Panacis Japonici saponin IV is preparing the application in blood lipid-lowering medicine Download PDFInfo
- Publication number
- CN103211828B CN103211828B CN201310165941.6A CN201310165941A CN103211828B CN 103211828 B CN103211828 B CN 103211828B CN 201310165941 A CN201310165941 A CN 201310165941A CN 103211828 B CN103211828 B CN 103211828B
- Authority
- CN
- China
- Prior art keywords
- panacis japonici
- rhizoma panacis
- concentration
- japonici saponin
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- TXUSTSJRABHHQP-UFGIQYKASA-N pulsatilla saponin D Natural products C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO[C@H]2O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC=C6[C@@H]7CC(C)(C)CC[C@@]7(CC[C@@]56C)C(=O)O)[C@]3(C)O)O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H](O)[C@H](O)[C@H]1O TXUSTSJRABHHQP-UFGIQYKASA-N 0.000 title claims abstract description 62
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 210000004369 blood Anatomy 0.000 title abstract description 19
- 239000008280 blood Substances 0.000 title abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 57
- 239000000287 crude extract Substances 0.000 claims description 24
- 230000007935 neutral effect Effects 0.000 claims description 21
- 239000006166 lysate Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000012567 medical material Substances 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 230000006837 decompression Effects 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000013461 design Methods 0.000 claims description 2
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 abstract description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 2
- 230000003516 hyperlipidaemic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 27
- 239000000243 solution Substances 0.000 description 18
- 239000007788 liquid Substances 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000012488 sample solution Substances 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 6
- 108010000912 Egg Proteins Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000002969 egg yolk Anatomy 0.000 description 5
- 235000013345 egg yolk Nutrition 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 5
- 229960002855 simvastatin Drugs 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000008802 xuezhikang Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 238000013094 purity test Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000168720 Panax japonicus Species 0.000 description 2
- 235000003174 Panax japonicus Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- -1 triterpenoid compound Chemical class 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical group O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- JCICPMFMVXNAOW-BHPIZNGBSA-N chikusetsusaponin VI Natural products CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO[C@@H]5OC[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C JCICPMFMVXNAOW-BHPIZNGBSA-N 0.000 description 1
- JCICPMFMVXNAOW-UHFFFAOYSA-N chikusetsusaponin vi Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)O)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O JCICPMFMVXNAOW-UHFFFAOYSA-N 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses Rhizoma Panacis Japonici saponin IV and prepare the application in blood lipid-lowering medicine.Effect experiment shows that Rhizoma Panacis Japonici saponin IV significantly can reduce TG, TC and LDL-C content in egg-nog hyperlipemia in mice serum, raises HDL-C content; Safety is high, and effect for reducing blood fat affirmative, for clinical treatment hyperlipidaemic conditions provides a kind of selection newly.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Rhizoma Panacis Japonici saponin IV and preparing the application in blood lipid-lowering medicine.
Background technology
Hyperlipidemia is a breakneck disease, can cause coronary heart disease and apoplexy; Prevalence is high, and global hyperlipidemia prevalence is 7.6%, and U.S.'s prevalence is up to 50%, and Chinese prevalence is up to 30%, only just reaches 1.6 hundred million more than at Chinese number of patients; The prevalence of hyperlipidemia is rising year by year, and treatment drops into huge.
An existing clinical line lipid lowerers mainly statins (simvastatin etc.).Statins is by the rate-limiting enzyme HMG-CoA reductase of T suppression cell inner cholesterol synthesis commitment, make hepatic cholesterol biosynthesis block, reduce endocellular liberation cholesterol, then feedback raises the expression of cell surface low density lipoprotein, LDL (LDL) receptor, make cell ldl receptor increased number and increased activity, accelerate the removing of low-density lipoprotein cholesterol (LDL-C) in blood, thus reduce blood fat; But statins has serious untoward reaction, can hepar damnification be caused, cause transaminase to raise, myalgia, serum creatine creatase (CK) raise, severe patient can cause rhabdomyolysis, acute renal failure.
Therefore, research at present has the new Chinese medicine that effect for reducing blood fat is definite, safety is high, quality controllable, has important social meaning and economic implications.
Summary of the invention
Rhizoma Panacis Japonici is Araliaceae Radix Ginseng, belongs to the dry root of herbaceos perennial Panax japonicus C.A.Mey., containing multiple saponin, volatile oil, saccharide and several amino acids.Former is a kind of famous and precious Chinese herbal medicine among the people, has now recorded in the Pharmacopoeia of the People's Republic of China, the similar Radix Ginseng of medicinal function and Radix Notoginseng.Rhizoma Panacis Japonici is born in by hillside limes marginis, dark and damp area or rock ditch ravine, is mainly distributed in the ground such as Guizhou, Hunan, Yunnan, Anhui, Jiangxi, Hubei.Annual autumn excavates, and removing stem and leaf, separates fleshy tap root, rhizome is removed crust, dry or dry in the shade and can be used as medicine.Begin to be loaded in supplementary Amplifications of the Compendium of Materia Medica.Sweet, the micro-hardship of Rhizoma Panacis Japonici, temperature.Have the multiple efficacies such as blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, strengthening by means of tonics, the strengthening by means of tonics effect of existing similar Radix Ginseng, has again the eliminating stasis to stop pain of similar Radix Notoginseng, hemostasis, phlegm-dispelling functions, is mainly used in weakness, chronic cough hemoptysis, cough with copious phlegm, traumatic injury after being ill.
The object of this invention is to provide a kind of Rhizoma Panacis Japonici saponin IV and prepare the application in blood lipid-lowering medicine.
The object of the invention is to be achieved through the following technical solutions:
Rhizoma Panacis Japonici saponin IV is Oleanolic triterpenic glycoside, and its chemical constitution is clear and definite, as formula I;
Formula I Rhizoma Panacis Japonici saponin IV structure
The invention provides Rhizoma Panacis Japonici saponin IV as the application of active component in the medicine of preparation blood fat reducing, purity >=90% of the Rhizoma Panacis Japonici saponin IV preferably used.
Above-mentioned Rhizoma Panacis Japonici saponin IV prepares by the following method:
A, medicinal material extract: get Rhizoma Panacis Japonici medical material, the ethanol or the methanol eddy that add Rhizoma Panacis Japonici medical material 6-12 times amount extract 1-3 hour, filter, obtain filtrate, medicinal residues use the ethanol of Rhizoma Panacis Japonici medical material 6-12 times amount or methanol eddy to extract again 1-3 time, each 1-3 hour, filter, merging filtrate, reclaim under reduced pressure alcohol, to without alcohol taste, is mixed with the extracting solution containing 0.05-0.5g medical material/ml;
The HPD722 macroporous resin column enrichment of b, extracting solution: HPD722 macroporous resin column on extracting solution, wash with water and do not permitted reaction to without vertical, mass concentration is the neutral alcohol solution remove impurity of 5%, the mass concentration of 5-8 times amount column volume is the neutral alcohol eluant solution of 60%, collect the neutral alcohol eluent that mass concentration is 60%, recycling design is near dry, and drying under reduced pressure, obtains crude extract;
The precipitate and separate of c, crude extract: get crude extract and add the methanol solution that mass concentration is 8%, dissolving is mixed with 0.067g/ml lysate, acid adding adjustment lysate pH3.5, precipitant dichloromethane is added in lysate, abundant mixing, leaves standstill more than 24h, filters, collecting precipitation, drying under reduced pressure obtains the separator of crude extract;
Prepared by d, Rhizoma Panacis Japonici saponin IV compound ODS column purification: SunChrom filler, particle diameter 10 μm, 50mm × 250mm; Mobile phase: the volume ratio of methanol-0.5% aqueous formic acid=65:35(and methanol and mass percent concentration 0.5% aqueous formic acid is 65:35); Flow velocity: 20ml/min, determined wavelength: 203nm; Collect corresponding fraction, after decompression and solvent recovery, drying under reduced pressure obtains Rhizoma Panacis Japonici saponin IV monomer.
The ethanol of above-mentioned reflux, extract, or the mass concentration of methanol are 70-90%, and the mass concentration of preferred alcohol or methanol is 90%.
The part by weight of above-mentioned lysate and precipitant is 1-2:1-2, and the part by weight of preferred dissolution liquid and precipitant is 1:1.
The dosage form of medicine of the present invention can be any one dosage form pharmaceutically approved.
Rhizoma Panacis Japonici saponin IV of the present invention preferably prepares by the following method:
A, medicinal material extract: get Rhizoma Panacis Japonici medical material, pulverize, the mass concentration adding Rhizoma Panacis Japonici medical material 10 times amount is 90% soak with ethanol 2h, heating and refluxing extraction 2h, filter, obtain filtrate, medicinal residues are 90% alcohol reflux 2h, 2h by Rhizoma Panacis Japonici medical material 9 times amount, 8 times amount mass concentrations respectively, filter, obtain filtrate respectively, merge three filtrates, decompression recycling ethanol is extremely without alcohol taste, thin up is to 0.1g crude drug/ml, and this is the sample solution of macroporous resin column enrichment;
The HPD722 macroporous resin column enrichment of b, extracting solution: the sample solution 200ml getting above-mentioned 0.1g crude drug/ml, is added to (the heavy 60g of wet resin, column volume is 75ml) in HPD722 macroporous resin column, is washed to and is not permitted without molish(is vertical) reaction; Use 5% neutral alcohol remove impurity instead, the amount of 5% neutral alcohol used is the column volume of 10 times amount; Use 60% neutral alcohol eluting again instead, the amount of 60% neutral alcohol used is the column volume of 6 times amount; Collect 60% neutral alcohol eluent, decompression recycling ethanol and too much moisture are near dry, and drying under reduced pressure obtains crude extract.
The precipitate and separate of c, crude extract: get crude extract 6.7g, adding concentration is 8% methanol aqueous solution 100ml, ultrasonic dissolution, be mixed with 0.067g/ml lysate, add dilute hydrochloric acid, the pH=3.5 of adjustment lysate, in lysate: precipitant=1:1 ratio adds precipitant dichloromethane, abundant mixing, leave standstill 24h, sucking filtration, collecting precipitation, drying under reduced pressure at 70 DEG C, obtains the separator of crude extract.
Prepared by d, Rhizoma Panacis Japonici saponin IV compound ODS column purification: Chinese nation high performance liquid chromatograph; NP7000 double pump; NU3000UV/Vis detector; DAC-HB50 dynamic axial compression column (SunChrom filler, particle diameter 10 μm, 50mm × 250mm); Mobile phase: methanol-containing 0.5% aqueous formic acid=65:35; Flow velocity: 20ml/min, sample size: 5ml, determined wavelength: 203nm; Collect corresponding fraction, after decompression and solvent recovery, drying under reduced pressure obtains Rhizoma Panacis Japonici saponin IV monomer.
Repeatedly prepare, q.s Rhizoma Panacis Japonici saponin IV compound can be prepared.
Above-mentioned Rhizoma Panacis Japonici saponin IV can be prepared into the compositions of blood fat reducing with pharmaceutically acceptable carrier or customary adjuvant as active component.Above-mentioned pharmaceutically acceptable carrier comprises the adjuvant of oral formulations adjuvant or Parenteral.Route of administration can be oral, injection, topical etc.According to technical scheme of the present invention, said composition can be oral formulations or injection preparation.Wherein oral formulations comprises capsule, soft capsule, granule, oral liquid, tablet, drop pill etc.Adjuvant used comprises: the customary adjuvant such as starch, sucrose, lactose, Icing Sugar, glucose, mannitol, xylitol, Polyethylene Glycol, isopropyl alcohol, tween 80, glycerol, propylene glycol, microcrystalline Cellulose sodium, dextrin, cyclodextrin, sodium chloride, vitamin C, cysteine, citric acid, sodium thiosulfate, sodium sulfite, stearate and gelatin, preparation later stage preparation technology and equipment all belong to the routine techniques of pharmaceutical field, the present invention is not construed as limiting this, therefore will not describe in detail at this.
The specification of Rhizoma Panacis Japonici saponin IV hard capsule is: 0.21g/ grain (No. 2 capsules, wherein starch-containing adjuvant 5%, i.e. 0.01g); Consumption per day: each 2-4 grain, every day 6-12 grain.
Rhizoma Panacis Japonici saponin IV of the present invention extracts to obtain from natural Chinese medicine Rhizoma Panacis Japonici, and effect experiment shows that Rhizoma Panacis Japonici saponin IV significantly can reduce TG, TC and LDL-C content in egg-nog hyperlipemia in mice serum, raises HDL-C content; Safety is high, and effect for reducing blood fat certainly.
Beneficial effect of the present invention compared with the prior art: the present invention shows that Rhizoma Panacis Japonici saponin IV has the effect of significant blood fat reducing first, therefore, is developed to blood lipid-lowering medicine by Rhizoma Panacis Japonici saponin IV and has broad application prospects.
Accompanying drawing explanation
Fig. 1 is the mass spectrum of Rhizoma Panacis Japonici saponin VI.
Fig. 2 is the hydrogen spectrogram of Rhizoma Panacis Japonici saponin VI.
Fig. 3 is the carbon spectrogram of Rhizoma Panacis Japonici saponin VI.
Fig. 4 is the HPLC chromatogram of Rhizoma Panacis Japonici saponin IV.
Fig. 5 respectively organizes cell oil red O stain figure.
Detailed description of the invention
Embodiment 1: the preparation of Rhizoma Panacis Japonici saponin IV, Structural Identification and purity testing thereof
The preparation of Rhizoma Panacis Japonici saponin IV compound:
Medicinal material extract: get Rhizoma Panacis Japonici medical material, pulverize, the mass concentration adding Rhizoma Panacis Japonici medical material 10 times amount is 90% soak with ethanol 2h, heating and refluxing extraction 2h, filter, obtain filtrate, medicinal residues are 90% alcohol reflux 2h, 2h by Rhizoma Panacis Japonici medical material 9 times amount, 8 times amount mass concentrations respectively, filter, obtain filtrate respectively, merge three filtrates, decompression recycling ethanol is extremely without alcohol taste, thin up is to 0.1g crude drug/ml, and this is the sample solution of macroporous resin column enrichment;
The HPD722 macroporous resin column enrichment of extracting solution: the sample solution 200ml getting above-mentioned 0.1g crude drug/ml, is added to (the heavy 60g of wet resin, column volume is 75ml) in the HPD722 macroporous resin column handled well according to a conventional method, is washed to and reacts without molish; Use 5% neutral alcohol remove impurity instead, the amount of 5% neutral alcohol used is the column volume of 10 times amount; Use 60% neutral alcohol eluting again instead, the amount of 60% neutral alcohol used is the column volume of 6 times amount.Collect 60% neutral alcohol eluent, decompression recycling ethanol and too much moisture are near dry, and transfer in container, drying under reduced pressure obtains crude extract.Repeated multiple times preparation, obtains the crude extract of q.s.
The precipitate and separate of crude extract: get crude extract 6.7g, adding concentration is 8% methanol aqueous solution 100ml, ultrasonic dissolution, be mixed with 0.067g/ml lysate, add dilute hydrochloric acid, the pH=3.5 of adjustment lysate, in lysate: precipitant=1:1 ratio adds precipitant dichloromethane, abundant mixing, leave standstill 24h, sucking filtration, collecting precipitation, drying under reduced pressure at 70 DEG C, obtains the separator of crude extract.Repeated multiple times preparation, obtains the crude extract separator of q.s.
Prepared by Rhizoma Panacis Japonici saponin IV compound ODS column purification: Chinese nation high performance liquid chromatograph; NP7000 double pump; NU3000UV/Vis detector; DAC-HB50 dynamic axial compression column (SunChrom filler, particle diameter 10 μm, 50mm × 250mm); Mobile phase: methanol-0.5% aqueous formic acid=65:35; Flow velocity: 20ml/min, sample size: 5ml, determined wavelength: 203nm.Collect corresponding fraction, after decompression and solvent recovery, transfer in container, drying under reduced pressure obtains Rhizoma Panacis Japonici saponin IV monomer.Repeatedly prepare, prepare q.s Rhizoma Panacis Japonici saponin IV compound.
The Structural Identification of Rhizoma Panacis Japonici saponin IV compound:
Compound 1, white powder (methanol), Liebermann-Burchard and Molish reaction is all positive.The colour developing of silica gel thin-layer ethanol solution of sulfuric acid is aubergine, shows for triterpenoid compound.ESI-MS m/z：925.3[M-H]
-。
1h-NMR(300MHz, Pyr) spectrum in: δ 0.83 ~ 1.28(each 3H, s) be 7 methyl signals, in conjunction with
13c-NMR(75MHz, Pyr) in spectrum, δ 176.39 points out is likely carbonyl on ester bond, δ 172.45 is a carbonyl carbon signals, prompting is likely the carbonyl on carboxylic acid key, δ 144.12,123.87(C-12,13) double key carbon signal, δ 108.65,107.02 and 95.74 points out on this compound structure and is connected with 3 sugar, infers that this compound is be connected with three sugared triterpene saponin componds, sees Fig. 1.(Fujioka N in reference literature, Kohda H, Yamasaki K, Deng .Dammarane and oleanane saponins from callus tissue of Panax japonicus [J] .Phytochemistry, 1989,28 (7): 1855-1858.) spectral data, identifies that this compound is Rhizoma Panacis Japonici saponin VI (Chikusetsusaponin VI), sees formula I.
Formula I Rhizoma Panacis Japonici saponin IV structure
Hydrogen spectrum and carbon modal data as follows, spectrogram is shown in Fig. 2 and Fig. 3.
1H NMR(300MHz，Pyr)δ6.31(d，J=7.8Hz，1H)，6.12(s，1H)，5.41(s，1H)，3.35(d，J=7.7Hz，1H)，3.19(d，J=10.8Hz，1H)，1.28(3H，s，2×CH
3)，1.08，0.96，0.91，0.89，0.83(3H，s，5×CH
3)。
13C NMR(75MHz,Pyr)δppm:38.64(C-1)，26.54(C-2)，89.19(C-3)，39.48(C-4)，55.74 (C-5)，18.48(C-6)，33.11(C-7)，39.91(C-8)，48.00(C-9)，36.94(C-10)，23.74(C-11)，123.87(C-12)，144.12(C-13)，42.13(C-14)，28.16(C-15)，23.64(C-16)，46.99(C-17)，41.74(C-18)，46.20(C-19)，30.75(C-20)，34.01(C-21)，32.54(C-22)，28.25(C-23)，16.91(C-24)，15.49(C-25)，17.46(C-26)，26.09(C-27)，176.39(C-28)，33.11(C-29)，23.75(C-30)，3-O-Glc A，107.02(C-1’)，75.32(C-2’)，76.02(C-3’)，78.91(C-4’)，76.64(C-5’)，172.45(C-6’)，Ara，108.65(C-1’’)，82.47(C-2’’)，87.81(C-3’’)，74.13(C-4’’)，62.66(C-5’’)，28-O-Glc，95.74(C-1’’’)，74.13(C-2’’’)，79.28(C-3’’’)，71.16(C-4’’’)，78.81(C-5’’’)，62.25(C-6’’’)。
The purity testing of Rhizoma Panacis Japonici saponin IV compound:
Shimadzu LC-20A high performance liquid chromatograph; SPD-20A UV/Vis detector; Chromatographic column: Boston ODS chromatographic column (4.6 × 150mm, 5 μm); Mobile phase: acetonitrile-mass percent 0.05% phosphoric acid water=34:66(volume ratio); Determined wavelength: 203nm; Flow velocity: 1ml/min; Column temperature: 30 DEG C; Sample size: 10 μ l, acquisition time: 19min.
Get and prepare Rhizoma Panacis Japonici saponin IV monomer 10mg, put in 10ml volumetric flask, add mobile phase and dissolve, standardize solution, obtain Rhizoma Panacis Japonici saponin IV solution that concentration is 1mg/ml, sample introduction 10 μ l carries out purity testing.
Measurement result: appearance time: 13.782min; Peak area: 351704.594; Content: 94.27%(calculates by area normalization method).HPLC spectrogram is shown in Fig. 4.
Embodiment 2: the preparation of Rhizoma Panacis Japonici saponin IV
The preparation of Rhizoma Panacis Japonici saponin IV compound:
Medicinal material extract: get Rhizoma Panacis Japonici medical material, pulverizes, and the mass concentration adding Rhizoma Panacis Japonici medical material 12 times amount is that 90% methanol soaks 2h, heating and refluxing extraction 3h, filter, obtain filtrate, medicinal residues respectively with Rhizoma Panacis Japonici medical material 9 times amount, 10 times amount mass concentrations be 90% methanol eddy extraction 2h, 2h, filter, obtain filtrate respectively, merge three filtrates, reclaim under reduced pressure methanol is extremely without alcohol taste, thin up is to 0.1g crude drug/ml, and this is the sample solution of macroporous resin column enrichment;
The HPD722 macroporous resin column enrichment of extracting solution: the sample solution 200ml getting above-mentioned 0.1g crude drug/ml, is added to (the heavy 60g of wet resin, column volume is 75ml) in the HPD722 macroporous resin column handled well according to a conventional method, is washed to and reacts without molish; Use 5% neutral alcohol remove impurity instead, the amount of 5% neutral alcohol used is the column volume of 10 times amount; Use 60% neutral alcohol eluting again instead, the amount of 60% neutral alcohol used is the column volume of 6 times amount.Collect 60% neutral alcohol eluent, decompression recycling ethanol and too much moisture are near dry, and transfer in container, drying under reduced pressure obtains crude extract.Repeated multiple times preparation, obtains the crude extract of q.s.
The precipitate and separate of crude extract: get crude extract 6.7g, adding concentration is 8% methanol aqueous solution 100ml, ultrasonic dissolution, be mixed with 0.067g/ml lysate, add dilute hydrochloric acid, the pH=3.5 of adjustment lysate, in lysate: precipitant=1:1 ratio adds precipitant dichloromethane, abundant mixing, leave standstill 24h, sucking filtration, collecting precipitation, drying under reduced pressure at 70 DEG C, obtains the separator of crude extract.Repeated multiple times preparation, obtains the crude extract separator of q.s.
Prepared by Rhizoma Panacis Japonici saponin IV compound ODS column purification: Chinese nation high performance liquid chromatograph; NP7000 double pump; NU3000UV/Vis detector; DAC-HB50 dynamic axial compression column (SunChrom filler, particle diameter 10 μm, 50mm × 250mm); Mobile phase: methanol-0.5% aqueous formic acid=65:35; Flow velocity: 20ml/min, sample size: 5ml, determined wavelength: 203nm.Collect corresponding fraction, after decompression and solvent recovery, transfer in container, drying under reduced pressure obtains Rhizoma Panacis Japonici saponin IV monomer.
The external blood fat reducing experiment of embodiment 3 Rhizoma Panacis Japonici saponin IV
1. sample is to the preparation of drug solns
Take Rhizoma Panacis Japonici saponin IV (preparing according to embodiment 1 method) 0.41mg in 15ml centrifuge tube by 100,000/electronic balance precision, add 10ml DMEM in high glucose culture medium and dissolve, obtain Rhizoma Panacis Japonici saponin IV sample solution that concentration is 41 μ g/ml.
2. cell inoculation
Get the cell of 80-90% bottom the good covering culture bottle of growth conditions, become cell suspension through 0.25% trypsinization and count, adjustment cell concentration about 70,000 cells/ml, are inoculated in 24 orifice plates, every hole adds 1ml cell suspension, i.e. every hole inoculation about 70,000 cells.The cell inoculated is put in calorstat and continues to hatch.
3. experiment grouping
After 24 orifice plates of inoculating cell hatch 24h, take out, discard former culture medium, be divided into matched group, model group, dosing group, often group establishes 6 parallel multiple holes.Select 100,10,1,0.1 μm of ol/L as the adding consistency of compound.Matched group adds the DMEM in high glucose culture medium containing BSA, and model group adds the DMEM in high glucose culture medium containing final concentration 1mmol/L oleic acid, and each dosing group adds the DMEM in high glucose culture medium containing final concentration 1mmol/L oleic acid and each acute drug, and often group is 6 parallel holes.After pharmaceutical intervention 24h, suck culture supernatants, lower floor's cell per well adds cell pyrolysis liquid 50 μ l, cracking 30min on ice, by TG content in TG kit measurement cell (the every porocyte of cell counting about 170,000).
TG concentration=A sample/A mark × concentration of standard solution; Concentration of standard solution is 2mg/ml.
4. data statistic analysis
By Excel software to data analysis, experimental result is with mean+/-standard error
represent, adopt t method of inspection to compare group difference, P < 0.05 has significant difference, and P < 0.01 has pole significant difference.
5. oil red O stain: adopt conventional method to carry out oil red O stain.
The preparation of oil red O working solution:
Take 0.5g oil red dry powder, be dissolved in 100ml isopropyl alcohol, solution is heated to 100 DEG C 5 minutes, and ceaselessly stir, filtered while hot, refilter once after cooling, be made into the oil red storage liquid of 0.5%, the preservation of brown bottle sealing (or masking foil parcel lucifuge) 4 DEG C, is storage liquid, can preserves for a long time.Used time gets 6ml oil red storing solution and adds tri-distilled water 4ml and mix, and qualitative filter paper filters, and is finished after dilution in a few hours.
Staining procedure:
Carefully light and slowly remove culture fluid; With the light and slow rinsing 1-2 time of PBS; With the alcohol fixation 30min of 75%, cell membrane is fixed; With 60% isopropyl alcohol, mordant dyeing 1-2min is carried out to cell; At the bottom of the dyeing of oil red working solution 30min, liquid feeding 0.5-1ml overlay; With distilled water rinsing 2 times, removing excess dyestuff; Inverted light microscope is observed and is taken pictures, and preserves photo.6. experimental result
TG content in 6.1 administration group cells
In each group of cell, TG assay result is as shown in the table.
The content of table 1 administration group cell TG (n=6,
Note: compared with blank group, * represents that P < 0.05, * * represents P < 0.01;
Compared with model group,
▲represent P < 0.05,
▲ ▲represent P < 0.01.
Compared with matched group, model group cell TG content is that significance increases (P<0.01), illustrates that cell hyperlipidemia model is successfully established; Compared with model group, Rhizoma Panacis Japonici saponin IV administration group (100 μMs, 10 μMs) TG content significantly reduces (P<0.01, P<0.05), illustrates that Rhizoma Panacis Japonici saponin IV has cell effect for reducing fat.
6.2 oil red coloration results
Each group of cell dyeing situation as shown in Figure 5.
Can be found out clearly by Fig. 5: compared with matched group, model group has can be dyed red fat by oil red O in a large number and drip existence, shows that HepG2 cell hyperlipidemia model is successfully established; Administration group is compared with model group, and under high concentration (100 μMs), Rhizoma Panacis Japonici saponin IV administration group significantly can alleviate fatty heaped-up condition in cell, and in cell, red fat drips and all obviously reduces, and this is basically identical with TG value in the cell recorded.
Blood fat reducing experiment in the body of embodiment 4 Rhizoma Panacis Japonici saponin IV
1. experiment material
1.1 medicines and reagent: No. 12, mouse stomach syringe needle, plastic centrifuge tube 1.5ml, Fresh Egg some, Simvastatin Tablets (Shanghai Xinyi Wanxiang Pharmaceutical Co., Ltd., lot number: 080201), (Beijing WBL Peking University Biotech Co., Ltd assisted by Xuezhikang glue, lot number: 20080708), triglyceride determination test kit (the safe clinical reagent company limited of Beijing Northization, lot number: 20090318), T-CHOL test kit (the safe clinical reagent company limited of Beijing Northization, lot number: 20090318), low-density LP determination reagent box (the safe clinical reagent company limited of Beijing Northization, lot number: 20090318).
1.2 experimental facilitiess: low speed centrifuge (Anting Scientific Instrument Factory, Shanghai, model: 80-2B), microplate reader (Nanjing Huadong Electronic Group Medical Equipment LLC, model: DG5033A), high speed desktop refrigerated centrifuger (Changsha Xiang Yi centrifuge Instrument Ltd., model: TGL-16).
1.3 laboratory animals: Kunming mouse, 72, male and female half and half, body weight 18-22g.
2. modeling method
Lumbar injection 75% egg-nog normal saline solution 0.2ml/10g.75% egg yolk Emulsion: Fresh Egg some, bottom is opened an osculum and is vacated Ovum Gallus domesticus album, and egg yolk has put into beaker. and needle tubing probes into egg yolk thin film, draw egg yolk liquid, put in the graduated cylinder of 100ml, get 75ml egg yolk liquid with normal saline dilution to 100ml, be made into the egg-nog solution of 75%.(during modeling, use magnetic stirrer egg-nog, make egg-nog even, reduce error).
3. experimental technique
Kunming mouse 72,18-22g, male and female half and half, are divided into 6 groups at random, often organize 12.Be divided into Normal group, hyperlipidemia model group, Xuezhikang group, simvastatin group, Rhizoma Panacis Japonici saponin IV (preparing according to embodiment 1 method) high dose group (IV-H), Rhizoma Panacis Japonici saponin IV low dose group (IV-L).Gastric infusion, Normal group and hyperlipidemia model group gavage 0.5%CMCNa every day, gavage volume is 20ml/kg; Administration group gavage every day gives the medicine of same volume, altogether administration 14 days.The dosage of each administration group is respectively: Xuezhikang matched group dosage 1g/kg(concentration is 50mg/ml), simvastatin matched group dosage 0.014g/kg(concentration is 0.7mg/ml), to be respectively 0.18g/kg(concentration be 9mg/ml for the dosage of Rhizoma Panacis Japonici saponin IV high dose group and Rhizoma Panacis Japonici saponin IV low dose group), 0.06g/kg(concentration is 3mg/ml).Last administration is after 2 hours, and the equal lumbar injection 75% egg-nog normal saline solution 0.2ml/10g of each group, causes experimental hyperlipidemia.Mice modeling, after 20 hours, adopts and plucks eyeball blood collection method, centrifugalize serum, and according to T-CHOL, triglyceride, low density lipoprotein, LDL, high density lipoprotein test kit description operates, and measures the content of TC, TG, LDL-C, HDL-C.
4. experimental result:
Table 2 each treated animal blood lipid level table (n=12,
Note: compared with blank group, * represents that P < 0.05, * * represents P < 0.01;
Compared with model group,
▲represent P < 0.05,
▲ ▲represent P < 0.01.
Compared with Normal group, in model group mice serum, TG, TC, LDL-C content significantly raises, (P<0.01, P<0.01, P<0.01), HDL-C content significantly reduces (P<0.05);
Compared with model group, simvastatin group TG, TC, LDL-C content significantly reduce (P<0.01, P<0.01, P<0.01), and HDL-C content significantly increases (P<0.05); Compared with model group, Xuezhikang group TG, TC, LDL-C content significantly reduce (P<0.01, P<0.05, P<0.01), and HDL-C content is without significant change.
Compared with model group, Rhizoma Panacis Japonici saponin IV high dose group (IV-H) TG, TC, LDL-C content significantly reduces (P<0.01, P<0.01, P<0.05), HDL-C content significantly increases (P<0.01); Compared with model group, Rhizoma Panacis Japonici saponin IV low dose group (IV-L) TG, TC, LDL-C content significantly reduces (P<0.01, P<0.01, P<0.05), and HDL-C content is without significant change; Rhizoma Panacis Japonici saponin IV high dose effect for reducing fat is better than low dosage.
Embodiment 5 Rhizoma Panacis Japonici saponin IV tablet
Get the Rhizoma Panacis Japonici saponin IV obtained by embodiment 1 method, add tablet and commonly use adjuvant, preparation technology is prepared into tablet routinely.
Embodiment 6 Rhizoma Panacis Japonici saponin IV capsule
Get the Rhizoma Panacis Japonici saponin IV obtained by embodiment 1 method, add capsule and commonly use adjuvant, preparation technology is prepared into capsule routinely.
Embodiment 7 Rhizoma Panacis Japonici saponin IV oral liquid
Get the Rhizoma Panacis Japonici saponin IV obtained by embodiment 1 method, add oral liquid and commonly use adjuvant, preparation technology is prepared into oral liquid routinely.
Claims (8)
1. Rhizoma Panacis Japonici saponin IV is as the application of active component in the medicine of preparation reduction cholesterol, reduction low density lipoprotein, LDL and high density lipoprotein increasing content.
2. application according to claim 1, is characterized in that purity >=90% of described Rhizoma Panacis Japonici saponin IV.
3. application according to claim 1, is characterized in that described Rhizoma Panacis Japonici saponin IV prepares by the following method:
A, medicinal material extract: get Rhizoma Panacis Japonici medical material, the ethanol or the methanol eddy that add Rhizoma Panacis Japonici medical material 6-12 times amount extract 1-3 hour, filter, obtain filtrate, medicinal residues use the ethanol of Rhizoma Panacis Japonici medical material 6-12 times amount or methanol eddy to extract again 1-3 time, each 1-3 hour, filter, merging filtrate, reclaim under reduced pressure alcohol, to without alcohol taste, is mixed with the extracting solution containing 0.05-0.5g medical material/ml;
The HPD722 macroporous resin column enrichment of b, extracting solution: HPD722 macroporous resin column on extracting solution, wash with water and do not permitted reaction to without vertical, concentration is the neutral alcohol solution remove impurity of 5%, the concentration of 5-8 times amount column volume is the neutral alcohol eluant solution of 60%, collect the neutral alcohol eluent that concentration is 60%, recycling design is near dry, and drying under reduced pressure, obtains crude extract;
The precipitate and separate of c, crude extract: get crude extract and add the methanol solution that concentration is 8%, dissolving is mixed with 0.067g/ml lysate, acid adding adjustment lysate pH3.5, precipitant dichloromethane is added in lysate, abundant mixing, leaves standstill more than 24h, filters, collecting precipitation, drying under reduced pressure obtains the separator of crude extract;
Prepared by d, Rhizoma Panacis Japonici saponin IV compound ODS column purification: SunChrom filler, particle diameter 10 μm, 50mm × 250mm; Mobile phase: methanol-0.5% aqueous formic acid=65:35; Flow velocity: 20ml/min, determined wavelength: 203nm; Collect corresponding fraction, after decompression and solvent recovery, drying under reduced pressure.
4. application according to claim 3, is characterized in that the ethanol of described reflux, extract, or the concentration of methanol are 70-90%.
5. application according to claim 4, is characterized in that the ethanol of described reflux, extract, or the concentration of methanol are 90%.
6. application according to claim 3, is characterized in that the part by weight of described lysate and precipitant is 1-2:1-2.
7. application according to claim 6, is characterized in that the part by weight of described lysate and precipitant is 1:1.
8. application according to claim 1, is characterized in that the dosage form of described medicine is any one dosage form pharmaceutically approved.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310165941.6A CN103211828B (en) | 2013-05-07 | 2013-05-07 | Rhizoma Panacis Japonici saponin IV is preparing the application in blood lipid-lowering medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310165941.6A CN103211828B (en) | 2013-05-07 | 2013-05-07 | Rhizoma Panacis Japonici saponin IV is preparing the application in blood lipid-lowering medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103211828A CN103211828A (en) | 2013-07-24 |
| CN103211828B true CN103211828B (en) | 2015-08-05 |
Family
ID=48810214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310165941.6A Expired - Fee Related CN103211828B (en) | 2013-05-07 | 2013-05-07 | Rhizoma Panacis Japonici saponin IV is preparing the application in blood lipid-lowering medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103211828B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111150740A (en) * | 2020-01-13 | 2020-05-15 | 上海中医药大学 | Lipid-lowering active ingredient and lipid-lowering composition in panax japonicus and application of lipid-lowering active ingredient and lipid-lowering composition |
| CN113181200A (en) * | 2021-04-26 | 2021-07-30 | 北京大学 | Application of panax japonicus saponin IV in preparation of medicine for preventing and/or treating obesity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247416A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Blood lipid lowering application of total saponins of panax japonicus |
| CN102247391A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Application of panax japonicus saponin V to reduction of blood fat |
| CN102247400A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Blood lipid-reducing effect of panax japonicus polysaccharide |
-
2013
- 2013-05-07 CN CN201310165941.6A patent/CN103211828B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247416A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Blood lipid lowering application of total saponins of panax japonicus |
| CN102247391A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Application of panax japonicus saponin V to reduction of blood fat |
| CN102247400A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Blood lipid-reducing effect of panax japonicus polysaccharide |
Non-Patent Citations (2)
| Title |
|---|
| Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes;Li-Kun Han, et al.;《BMC Complementary and Alternative Medicine》;20050406;第5卷(第9期);第2页右栏第1段，第9页左栏第6-9行、右栏第2段， * |
| Rahul B. Birari, et al..Pancreatic lipase inhibitors from natural sources: unexplored potential.《Drug Discovery Today》.2007,第12卷(第19/20期),第879-889页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103211828A (en) | 2013-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104825463B (en) | The Metabolism regulation of plain boiled pork Ganodenna Lucidum P.E and the purposes of anti anoxia | |
| CN102133266B (en) | Preparation method for macroporous resin purifying extract of golden hemorrhoid fumigating-washing powder | |
| CN101863871A (en) | Total glycosides of Rhodiola rosea, medical application and preparation method thereof | |
| CN108143883A (en) | A kind of extracting method of dioscoreae septemlobae,rhizoma total saposins and application | |
| CN103211828B (en) | Rhizoma Panacis Japonici saponin IV is preparing the application in blood lipid-lowering medicine | |
| CN102247391B (en) | Application of panax japonicus saponin V to reduction of blood fat | |
| CN104873570B (en) | A kind of method for extraction and purification of Prunella vulgaris general flavone and its application | |
| CN102134268A (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN105601693B (en) | Ginseng saponin F1Preparation and its antitumor action | |
| CN104906083B (en) | The new application of iridoid | |
| CN106619652A (en) | Preparation method of spermacoce latifolia triterpenoids and application of spermacoce latifolia triterpenoids in preparation of glycosidase inhibitor drug | |
| CN101703669B (en) | Smilax china effective fractions and extraction as well as purification process thereof | |
| CN111153955A (en) | Gynostemma pentaphylla extract with lipid-lowering effect and preparation method and application thereof | |
| CN101531721B (en) | Industrial preparation method for triterpenoid saponin monomer | |
| CN103524593A (en) | Chikusetsusaponin IVa, derivatives thereof, preparation method thereof and application thereof to preparation of medicines | |
| CN104224952A (en) | Preparation method for total anthraquinones of rheum officinale with stable and uniform proportions of all components | |
| CN104758365A (en) | Method for extracting and preparing blood-sugar-reducing substance--secoiridoid glucoside compounds from seeds of Fraxinus rhynchophylla Hance | |
| CN105193824B (en) | A kind of ganodenic acid acid activity position and its preparation method and application | |
| CN104257756B (en) | The application in preparing hypoglycemic medicine of a kind of Cortex Mori fatty oil | |
| CN102247416B (en) | Blood lipid lowering application of total saponins of panax japonicus | |
| CN106317157A (en) | Polyhydroxy diketone cucuribitane triterpene as well as preparation method and application thereof | |
| CN105434442A (en) | Synsepalum dulcificum leaf extract and application of same in preparation of drugs or health products used for treating diabetes or hyperlipidemia | |
| CN102247400B (en) | Blood lipid-reducing effect of panax japonicus polysaccharide | |
| CN110585221A (en) | Albizzia julibrissin new lignan compound for improving steatosis and application thereof | |
| CN105330713B (en) | 3beta-acetoxyl ginsenoside F1 and extraction method and medicine application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150805 |